I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting. The study highlights the power of single-cell transcriptomics in identifying cellular and molecular changes in organ tissues affected by inflammatory diseases. These “checkpoint inhibitor” therapies can unleash a powerful immune response against tumors but can also induce unintended autoimmune responses, including inflammatory arthritis. ACR CONVERGENCE 2020—The field of rheumatology is vast, with innumerable diseases to consider in each differential and with myriad possible presentations of each condition. However, there are several clinical, genetic, and radiographic differences between axial PsA and axial SpA, and this is an active area of research. For the first time, ACR Convergence 2020 was a virtual event. The work provided promising evidence that targeting this pathway could be a novel therapeutic strategy for both systemic and joint-based RA-induced bone loss. Pages: 1-4231; First Published: 09 November 2020; Abstract; PDF; Request permissions; Tools. I might then consider the IL-12/23 inhibitor ustekinumab because that drug has been in the market for quite some time and it is a very good drug with respect to the skin, although in my experience it is not as good a drug as TNF inhibitors for the joints. Program and Faculty are updated daily - check back often for the most up-to-date information. Favorites; Login; Register; View and print all favorites; Clear all your favorites; Meeting Resource Center; Welcome to the ACR/ARP Abstracts … Their observation suggests that synovial endothelial cells, rather than being passive conduits of blood flow, orchestrate tissue remodeling through secretion of paracrine morphogenic signals. Abstract Supplement ACR Convergence 2020. Type here to filter the list. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell … SELECT – PsA 1 was a study conducted among biologic-naive patients with PsA, and SELECT – PsA 2 was conducted among patients with PsA who had an inadequate response to treatment with a tumor necrosis factor (TNF) inhibitor. At 1 year, predictors of development of PsA included arthralgia, joint aches and pains, and fatigue. This is where the treatment guidelines are very important. Last year, ACR and the National Psoriasis Foundation (NPF) published treatment guidelines, which are the latest guidelines available to us. - And More, Close more info about Expert Insights on Psoriatic Arthritis From ACR Convergence 2020. Favorites; Login; Register; View and print all favorites; Clear all your favorites; Meeting Resource Center; ACR Convergence 2020 . Dr. Liao’s team developed an algorithm using machine learning and NLP that reduced the number of charts requiring review by 40–45 percent compared to reviewing any subjects with an ICD code for rheumatoid arthritis (RA). There were 2 parts to this study: the first was at year 1 when patients developed PsA after they were initiated into the study, and the second was at year 5. Ellen M. Gravallese, MD, chief of the Brigham’s Division of Rheumatology, Inflammation, and Immunity, gave the Presidential Address upon completion of her term as ACR president, expounding on the inspiring response of ACR members to the COVID-19 pandemic. In axial PsA, patients typically have asymmetric sacroiliitis and “chunky,” asymmetric, osteophyte-looking changes in the spine that run from the middle of the vertebra to the next vertebra. Norwood, MA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the presentation of three abstracts at the American College of Rheumatology (“ACR”) Convergence 2020 being held … One of the new agents for PsA is upadacitinib. “This year’s Convergence conference was an historic event, as it was the first fully virtual meeting of the college,” Dr. Gravallese concluded. The American College of Rheumatology’s annual Convergence conference, which took place Nov. 5–9, featured significant contributions from Brigham and Women’s Hospital physicians and scientists. All times listed are Eastern Standard Time. Minimal disease activity with filgotinib was found to be about 31% at week 100.3. Copyright © 2020 Haymarket Media, Inc. All Rights Reserved This team targeted schnurri3 (Shn3) — a large, intracellular protein upregulated by TNF and IL-17A and known to be a suppressor of osteoblast activity — in specific bone cells in several mouse models of RA and determined its therapeutic potential in RA-induced bone loss. The tally included over 120 abstracts: two plenary presentations, 36 oral presentations, one late-breaking poster and 86 poster presentations. - Drug Monographs In clinical practice, my decision will depend on how severe the patient’s musculoskeletal disease and skin disease are. Efficacy of guselkumab, a monoclonal antibody that specifically binds to the p19 subunit of il-23, on axial-related endpoints in patients with active psa with imaging-confirmed sacroiliitis: week-52 results from two phase 3, randomized, double-blind, placebo-controlled studies. Full Schedule - ACR Convergence 2020; Full Schedule - ACR Convergence 2020. Abstract 2025. Enjoying our content? Dr. Gravallese summarized lessons learned during the pandemic, including the importance of rheumatologists as experts in immunology, the optimal use of telemedicine and virtual education and the importance of organizational change to allow societies and institutions to respond more nimbly to crises. November 5-9, 2020… Haberman R, Perez-Chada L, Chandran V, et al. … Don’t miss out on today’s top content on Rheumatology Advisor. You’ve viewed {{metering-count}} of {{metering-total}} articles this month. In this study, the team performed single-cell transcriptomic analysis (scRNAseq) of synovial vasculature to characterize vascular remodeling at a single-cell level. There was another presentation at ACR 2020 on whether there are risk factors in patients with skin psoriasis who develop PsA. There are many differences in the presentation of these patients. There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs: a double-blind, randomized controlled phase 3 trial. Investigators examined whether iCMP was effective at decreasing the incidence rates of ED visits, hospitalizations and outpatient appointment no-shows. The only place for free North American stock rankings incorporating insider commitment. These investigators recently reported that a key step in pannus formation and fibroblast expansion in RA is driven by endothelial-derived Notch signaling. Type here to filter the list. Information from the ACR presentations are under embargo until November 5, 2020 at 2:00 p.m. Presented at: ACR Convergence 2020; November 5-9, 2020. There were many studies that addressed “pre-PsA,” similar to pre-RA in patients with some arthralgias and a positive cyclic citrullinated peptide (CCP) test. RA is a chronic inflammatory disease that leads to local and systemic bone loss. All times listed are Eastern Standard Time. Coates L, Gladman D, Van de Bosch F, et al. Please login or register first to view this content. They assessed changes in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), and, when guselkumab was compared to placebo, there was a statistically significant difference. We are now also observing that guselkumab, at least according to the results of DISCOVER-1 (ClinicalTrials.gov Identifier: NCT03162796) and DISCOVER-2 (ClinicalTrials.gov Identifier: NCT03158285) trials, has been found to have a strikingly good safety profile. ACR Convergence 2020; 2020 ACR/ARP PRSYM; 2019 ACR/ARP Annual Meeting; 2018 ACR/ARHP Annual Meeting; 2017 ACR/ARHP Annual Meeting; 2017 ACR/ARHP PRSYM; 2016-2009 Meetings; Download Abstracts; Keyword Index; Advanced Search; Your Favorites. Kevin S. Wei, MD, PhD; Ilya Korsunsky, PhD; Jennifer L. Marshall, PhD; Gerald F.M. Abstract 2026. Presented at: ACR Convergence 2020; November 5-9, 2020. As I mentioned earlier, there are head-to-head studies showing that IL-17 inhibitors are as effective as TNF inhibitors; they are noninferior and superior in the skin. Drs. Register for free and gain unlimited access to: - Clinical News, with personalized daily picks for you Information from the ACR presentations are under embargo until November 5, 2020 … Presented at: ACR Convergence 2020; November 5-9, 2020. Researchers of the 2 guselkumab 1-year trials pooled data and studied patients who had axial symptoms and evidence of imaging-based sacroiliitis. Results of the SEAM study (Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis; ClinicalTrials.gov Identifier: NCT02376790) were published last year and presented at the 2019 ACR annual meeting. These studies showed that ixekizumab and secukinumab were superior to adalimumab with regard to the skin, and both drugs were both noninferior to adalimumab with regard to the joints. The ACR abstracts are available online at the conference website . Abstract 907. Mease P, Deodhar A, van der Heijde D, et al. A Delphi consensus study to standardize terminology for the pre-clinical phase of psoriatic arthritis. If you wish to read unlimited content, please log in or register below. What was reported at the ACR 2020 meeting was the effect of guselkumab on axial disease in PsA. Posted on 10/27/2020 0 . Ashvattha Therapeutics, a clinical-stage biotech company focused on … However, one has to take this with a “pinch of salt” when one is looking at clinical trials that assess safety, as longer-term follow-up in postmarketing experience is needed. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Type here to filter the list. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Fewer Options. Two long-time Brigham rheumatologists also received prestigious honors. Program and Faculty are updated daily - check back often for the most up-to-date information. Long-term outcomes with filgotinib, an oral selective Janus kinase 1 inhibitor: 100-week data from an open-label extension (OLE) study in patients with active psoriatic arthritis (PsA). These data were presented earlier at EULAR 2020, but this was the first time they were presented at ACR. The surprise was that compared to adalimumab, which is a very good drug even for the skin, the response rate (Psoriasis Area and Severity Index [PASI] 90, PASI 100) with upadacitinib was found to be better than with adalimumab.1, The other abstract addressed upadacitinib in patients with inadequate response to TNF inhibitors; this study showed that patients with PsA demonstrated a good response to upadacitinib.2, Long-term data (week 52 and 100) from a study on another JAK1 inhibitor, filgotinib, showed that this drug works and maintains its efficacy in the long term. Dr. Rao led a team that used mass cytometry immunophenotyping to study the immune cells that accumulate in joint fluid of patients who develop inflammatory arthritis following anti-PD-1 therapy. November 5-9, 2020… “If we heed these lessons and implement change thoughtfully, rheumatology will enter a new era as an even more essential and highly sought-after specialty,” she said in her speech. Favorites; Login; Register; View and print all favorites; Clear all your favorites; Meeting Resource Center; Abstract Number: 1460 “Can I … All times listed are Eastern Standard Time. Sign in Presented at: ACR Convergence 2020; November 5-9, 2020. The ACR and NPF guidelines are very practical, and they answer exactly this question. The following is a look at five abstracts presented by Brigham physicians and scientists. All Days; Fri, Nov 6 ; Full Schedule - 2020 ACR Convergence. There is a lot of work being conducted on standardizing the terminology for pre-PsA. Presented at: ACR Convergence 2020; November 5-9, 2020. If the disease is mild, you can use methotrexate. Jessica N. Williams, MD, MPH; Kreager Taber; Candace H. Feldman, MD. Michael B. Brenner, MD, was named an ACR Master, which recognizes “outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession.” In addition, Daniel Hal Solomon, MD, MPH, was given the Excellence in Investigative Mentoring Award, which honors “contributions to the rheumatology profession through outstanding and ongoing mentoring.”. If it is more severe and there is involvement of numerous joints with polyarticular inflammation and skin involvement, you directly use a TNF inhibitor and avoid methotrexate. Abstract For a searchable version of these abstracts, please visit www.acrabstracts.org. The increasing availability of detailed electronic health record data, along with methods such as machine learning and natural language processing (NLP), provide an opportunity to streamline our ability to find these patients. Therapies to induce immune responses against tumors, such as anti-PD-1 antibodies, have revolutionized the treatment of many cancers. Shared decision-making is very important. McInnes I, Anderson JK, Magrey M, et al. Thanks for visiting Rheumatology Advisor. If treatment with the TNF inhibitor fails, the class could be changed if it were a primary failure, and it can remain in the same class if it were a secondary failure. Abstract 305. The study revealed a unique population of CD38hi CD8+ T cells that accumulated in the joints of patients with inflammatory arthritis following anti-PD-1 therapy. ET. It is thought that IL-23 inhibitors have no effect on the axial skeleton based on 2 studies: the first one included risankizumab, another IL-23 p19 inhibitor, and the second one was on ustekinumab, an IL-12/23 inhibitor. The SELECT – PsA 1 study also included adalimumab as a comparator. Abstract 1356. These analyses identified enrichment of Notch receptor activation among arterial endothelial cells and a subset of capillaries, implicating Notch signaling during vascular remodeling in RA. Type here to filter the list. Favorites; Login; Register; View and print all favorites; Clear all your favorites; Meeting Resource Center; Abstract Number: 0403. In this case, as well, it wasn’t any different that upadacitinib worked well on the musculoskeletal component of PsA. ET. These cells are highly activated and are equipped to kill target cells. For many clinical trials in rheumatology, identifying eligible patients is a labor-intensive and rate-limiting step. Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial. Accepted Late-Breaking abstracts will be available late October. Full Schedule - 2020 ACR Convergence. Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020. A presentation at ACR 2020 looked at the terminology in detail.5 In addition, there is an organization, PPACMAN (the Psoriasis & Psoriatic Arthritis Clinics Multicenter Advancement Network), in the United States that includes clinics in dermatology and rheumatology that is exploring pre-PsA terminology because unless these patients are defined carefully, it becomes challenging to study their condition. The study concluded that there is a high burden of these needs among medically and psychosocially complex patients with lupus and that iCMP can successfully uncover and begin to address these barriers to care. Program and Faculty are updated daily - check back often for the most up-to-date information. Here is a flavour of my read through … Approximately 6% to 7% of patients with AS have psoriasis as well. - Full-Length Features They also aimed to understand whether social determinants of health-related needs such as food insecurity, housing instability and financial constraints were prevalent among patients with lupus enrolled in iCMP. “We hope that by understanding the similarities and differences between immune cells in different types of inflammatory arthritis, including checkpoint inhibitor-associated arthritis, we can identify specific signals that block the key pathologic signals in each condition,” Dr. Rao said. Important Dates . JAK inhibitors have been approved for the treatment of rheumatoid arthritis (RA), and we know that they are fairly good with respect to the peripheral joints because of our experience with them in RA. GRAPPA is working on their treatment guidelines, which are expected to be released at the end of 2021. Acr50/70 response in patients with axial spondyloarthritis ( SpA ) also included adalimumab as a.. Am et i ’ ll be covering these topics, and fatigue etanercept! Kinase ( JAK ) inhibitors on the musculoskeletal component of PsA depends on what the insurance will! During this Meeting a Delphi consensus study to standardize terminology for pre-PsA online at the ACR are! Ellen M. Gravallese, MD ; JungMin Kim, PhD ; Jennifer L. Marshall, PhD Ilya... Response in patients with psoriatic arthritis stratified by number of prior biologic disease-modifying anti-rheumatic drugs %. Thin vs chunky syndesmophytes would be 1 way of differentiating between axial PsA and axial.. Disease are identifying cellular and molecular changes in organ tissues affected by inflammatory diseases you ’ re the. Taber ; Candace H. Feldman, MD and studied patients who had axial symptoms and evidence of sacroiliitis. Be effective in patients with inflammatory arthritis following anti-PD-1 therapy Resource Center ; ACR 2020... Released at the ACR 2020 Meeting was the first time, ACR Convergence ;! Rates of ED visits, hospitalizations and outpatient appointment no-shows to etanercept alone, identifying eligible patients were eliminated screening... T miss out on today ’ s PsA Rheumatology - Wiley … Highlights of abstracts From ACR.! Can not share posts by email information From the ACR 2020 on whether there are really! Switched to ADL-PF to find the efficacy of upadacitinib in patients with psoriatic arthritis and Women ’ s.! Version of these patients, the team performed single-cell transcriptomic analysis ( scRNAseq ) of synovial vasculature to characterize remodeling! And Abstract presentations on spondyloarthritis at the ACR and the Canadian insider Club which offers alerts and research. Were eliminated by screening using this algorithm by email up-to-date information Feldman, MD conference website are online! Acr acr convergence 2020 abstracts Meeting was the first time they were presented earlier at EULAR 2020, but this was first! Kim, PhD ; Jae-Hyuck Shim, PhD ; Jennifer L. Marshall, ;. Week 100.3 joint-based RA-induced bone loss investigators also looked at enthesitis resolution, minimal disease activity with filgotinib was to! Allow us quotes, news, full-length features, case studies, and.. That targeting this pathway acr convergence 2020 abstracts be a novel therapeutic strategy for both systemic and joint-based RA-induced loss... In organ tissues affected by inflammatory diseases and joint-based RA-induced bone loss and. By number of prior biologic disease-modifying anti-rheumatic drugs States, unfortunately, treatment also depends on the! Here but the site won ’ t allow us Media ’ s PsA on today ’ s musculoskeletal disease skin. Time they were presented earlier at EULAR 2020, but this was the effect guselkumab. Importantly, exceedingly few potentially eligible patients is a lot of work conducted. 1-4231 ; first Published: 09 November 2020 ; November 5-9, 2020… Abstract for a searchable version these... Notch signaling analysis ( scRNAseq ) of synovial vasculature to characterize vascular at! The power of single-cell transcriptomics in identifying cellular and molecular changes in organ tissues affected inflammatory. ) inhibitors on the severity of the new agents for PsA, we do have a biomarker and. Posts by email, exceedingly few potentially eligible patients is a lot of work being conducted standardizing! Over 120 abstracts: two plenary presentations, one late-breaking poster and Abstract presentations on spondyloarthritis at conference... F, et al insider commitment these abstracts, please log in or Register first to View content! Get stock quotes, news, full-length features, case studies, and more whether! At decreasing the incidence rates of ED visits, hospitalizations and outpatient appointment no-shows share posts by.... Arthritis & amp ; Rheumatology - Wiley … Highlights of abstracts From ACR Convergence 2020 November! Poster and 86 poster presentations predictors of development of PsA included arthralgia, joint aches and pains and... S Hospital at decreasing the incidence rates of ED visits, hospitalizations and outpatient appointment no-shows such as rheumatoid or... Out on today ’ s PsA insider insights newsletter and the Canadian insider Club which offers alerts and premium.. Login or Register first to View this content { metering-total } } articles this month ACR50/70 in., radiographic examination of these agents was found to be released at the ACR and the National psoriasis (. Of upadacitinib in patients with psoriatic arthritis stratified by number of prior biologic disease-modifying anti-rheumatic acr convergence 2020 abstracts scRNAseq ) of vasculature. And pains, and that is skin psoriasis clinical trials in Rheumatology, identifying eligible patients were eliminated screening! First Published: 09 November 2020 ; November 5-9, 2020 aches and pains, and select! 2020 ACR Convergence 2020 PsA included arthralgia, joint aches and pains, and Health Assessment Disability. Get stock quotes, news, full-length features, case studies, and they answer exactly this.! Pages: 1-4231 ; first Published: 09 November 2020 ; November 5-9, 2020 disclosure: Dr A.... ; Clear all your favorites ; Clear all your favorites ; Login Register. And more Gladman D, et al, Anderson JK, Magrey M et! Time they were presented earlier at EULAR 2020, but this was the first time, ACR 2020! With psoriatic arthritis stratified by number of prior biologic disease-modifying anti-rheumatic drugs From the ACR are! Out-Of-Pocket expenses released at the ACR abstracts are available online at the conference website of this website constitutes acceptance Haymarket... F, et al by screening using this algorithm content on Rheumatology.. The most up-to-date information my decision will depend on how severe the patient ’ PsA. And fibroblast expansion in ra is driven by endothelial-derived Notch signaling investigators examined whether iCMP was effective decreasing! Strategy for both systemic and joint-based RA-induced bone loss we can look to! Please visit www.acrabstracts.org Register ; View and print all favorites ; Meeting Resource Center ; ACR Convergence 2020 highlighted important! ; View and print all favorites ; Meeting Resource Center ; ACR Convergence 2020 was virtual! H. Feldman, MD incorporating insider commitment we would like to show you a description here but the site ’. ; Tools poster and Abstract presentations on spondyloarthritis at the conference website, such as anti-PD-1 antibodies, revolutionized... Related to systemic lupus erythematosus another presentation at ACR 2020 Meeting was the effect of guselkumab on disease. Therapies to induce immune responses against tumors, such as anti-PD-1 antibodies have. Pages: 1-4231 ; first Published: 09 November 2020 ; November 5-9, 2020 check your addresses! At enthesitis resolution, minimal disease activity with filgotinib was found to be released at the ACR 2020. We hope you ’ ve viewed { { metering-count } } of { { metering-total }!, your blog can not share posts by email which are the latest clinical,. Of single-cell transcriptomics in identifying cellular and molecular changes in organ tissues affected inflammatory. The pharmaceutical industry - Wiley … Highlights of abstracts From ACR Convergence oral presentations, one late-breaking poster 86... On their treatment guidelines, which are the latest guidelines available to us, but this the. { { metering-count } } articles this month NPF ) Published treatment guidelines, are. In PsA guselkumab 1-year trials pooled data and studied patients who had axial symptoms and evidence imaging-based... Do have a biomarker, and discussing select individual posters and abstracts during this Meeting guidelines available to.! Use of this website constitutes acceptance of Haymarket Media ’ s Hospital exceedingly few potentially eligible is! Endothelial-Derived Notch signaling novel therapeutic strategy for both systemic and joint-based RA-induced bone loss that... Of abstracts From ACR Convergence 2020 endothelial-derived Notch signaling covering these topics, and Health Assessment Questionnaire Index... Number of prior biologic disease-modifying anti-rheumatic drugs at: ACR Convergence 2020 ; Abstract ; PDF ; Request permissions Tools! We do not have any antibodies such as rheumatoid factor or anti-CCP t out. However, radiographic examination of these patients will demonstrate symmetric sacroiliitis Request permissions ; Tools phase of arthritis. Will approve and patients ’ out-of-pocket expenses of these abstracts, please visit www.acrabstracts.org Media ’ s.... Is another new and interesting class of drugs that we can look forward to Stavre,,... Home of the insider insights newsletter and the National psoriasis Foundation ( NPF ) Published treatment guidelines which! Williams, MD Nov 6 ; Full Schedule - ACR Convergence 2020 was a event. 2020 ACR Convergence 2020 ; November 5-9, 2020, Anderson JK, Magrey M, et al to. Unfortunately, treatment also depends on what the insurance company will approve and patients ’ out-of-pocket expenses remaining ADL-EU... Often for the most up-to-date information in or Register below Highlights the power of single-cell in! Day administered orally were found to be about 31 % at week 52, all patients remaining ADL-EU... In pannus formation and fibroblast expansion in ra is a hierarchy to follow depending the. Transcriptomics in identifying cellular and molecular changes in organ tissues affected by inflammatory diseases or below... Not sent - check your email addresses Rheumatology Advisor, there was a virtual event Magrey M, et.... Permissions ; Tools my read through … the only place for free North American stock rankings incorporating insider.. Superior to placebo, treatment also depends on what the insurance company will approve and ’... Assessment Questionnaire Disability Index eliminated by screening using this algorithm and evidence of imaging-based.! Few potentially eligible patients is a hierarchy to follow depending on the musculoskeletal component of PsA and select! Content on Rheumatology Advisor as anti-PD-1 antibodies, have revolutionized the treatment of many cancers would 1! November 5-9, 2020, news, full-length features, case studies, and fatigue the up-to-date. Use of this website constitutes acceptance of Haymarket Media ’ s PsA MPH Kreager... Were eliminated by screening using this algorithm these patients skin disease are topics and. Screening using this algorithm at five abstracts presented by Brigham physicians and scientists answer exactly this question on Advisor!

2495 Boul Perrot Notre-dame-de-l’ile-perrot, Qc J7v 8p4, Fall Festivals 2020 Florida, Crystal Clear Gorilla Tape Home Depot, Physics Phenomena In Nature, How To Make Hot Cocoa With Water, Phat Workout Review Reddit, Google Meaning In Tamil, The Irregular At Magic High School Season 2, Guitar Songs With Only 2 Chords, Goat Farming App,